Cargando…
Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center
OBJECTIVE: Several studies have shown an increased risk of bullous pemphigoid (BP) when receiving dipeptidyl pepitidase-4 inhibitor (DPP-4i) treatment. The present study explored the associations of DPP-4i treatment with the clinical phenotypes and clinical course of BP. METHODS: We analyzed data of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332970/ https://www.ncbi.nlm.nih.gov/pubmed/36328578 http://dx.doi.org/10.2169/internalmedicine.0815-22 |
_version_ | 1785070551628251136 |
---|---|
author | Nakagawa, Yosuke Toyoda, Masao Saito, Nobumichi Kaneyama, Noriko Shimizu, Tomomichi Mabuchi, Tomotaka Fukagawa, Masafumi |
author_facet | Nakagawa, Yosuke Toyoda, Masao Saito, Nobumichi Kaneyama, Noriko Shimizu, Tomomichi Mabuchi, Tomotaka Fukagawa, Masafumi |
author_sort | Nakagawa, Yosuke |
collection | PubMed |
description | OBJECTIVE: Several studies have shown an increased risk of bullous pemphigoid (BP) when receiving dipeptidyl pepitidase-4 inhibitor (DPP-4i) treatment. The present study explored the associations of DPP-4i treatment with the clinical phenotypes and clinical course of BP. METHODS: We analyzed data of 146 patients with BP at Tokai University School of Medicine from December 1, 2009, to December 31, 2021. We obtained data by a retrospective medical record review and compared the bullous pemphigoid disease area index (BPDAI) between diabetes patients receiving DPP-4i treatment and those not receiving DPP-4i treatment. We employed multivariable linear regression models to explore the association between the DPP-4i treatment and the BPDAI scores. RESULTS: Among 53 BP patients with diabetes, 33 had developed BP during treatment with DPP-4i agents, among which vildagliptin was the most frequently used. The urticaria/erythema scores of the BPDAI were significantly lower in patients who developed BP while receiving DPP-4i treatment than among others. Of note, 69.2% of the patients who stopped DPP-4i treatment experienced complete remission, and the clinical course was more favorable in patients with lower scores for urticaria/erythema than among others. CONCLUSION: These findings suggest that, in patients who developed BP while receiving DPP-4i treatment, a noninflammatory phenotype may indicate a high likelihood that DPP-4i treatment contributes to the development of BP. The discontinuation of DPP-4i should be carefully considered in close consultation with dermatologists. |
format | Online Article Text |
id | pubmed-10332970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-103329702023-07-12 Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center Nakagawa, Yosuke Toyoda, Masao Saito, Nobumichi Kaneyama, Noriko Shimizu, Tomomichi Mabuchi, Tomotaka Fukagawa, Masafumi Intern Med Original Article OBJECTIVE: Several studies have shown an increased risk of bullous pemphigoid (BP) when receiving dipeptidyl pepitidase-4 inhibitor (DPP-4i) treatment. The present study explored the associations of DPP-4i treatment with the clinical phenotypes and clinical course of BP. METHODS: We analyzed data of 146 patients with BP at Tokai University School of Medicine from December 1, 2009, to December 31, 2021. We obtained data by a retrospective medical record review and compared the bullous pemphigoid disease area index (BPDAI) between diabetes patients receiving DPP-4i treatment and those not receiving DPP-4i treatment. We employed multivariable linear regression models to explore the association between the DPP-4i treatment and the BPDAI scores. RESULTS: Among 53 BP patients with diabetes, 33 had developed BP during treatment with DPP-4i agents, among which vildagliptin was the most frequently used. The urticaria/erythema scores of the BPDAI were significantly lower in patients who developed BP while receiving DPP-4i treatment than among others. Of note, 69.2% of the patients who stopped DPP-4i treatment experienced complete remission, and the clinical course was more favorable in patients with lower scores for urticaria/erythema than among others. CONCLUSION: These findings suggest that, in patients who developed BP while receiving DPP-4i treatment, a noninflammatory phenotype may indicate a high likelihood that DPP-4i treatment contributes to the development of BP. The discontinuation of DPP-4i should be carefully considered in close consultation with dermatologists. The Japanese Society of Internal Medicine 2022-11-02 2023-06-15 /pmc/articles/PMC10332970/ /pubmed/36328578 http://dx.doi.org/10.2169/internalmedicine.0815-22 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Nakagawa, Yosuke Toyoda, Masao Saito, Nobumichi Kaneyama, Noriko Shimizu, Tomomichi Mabuchi, Tomotaka Fukagawa, Masafumi Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center |
title | Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center |
title_full | Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center |
title_fullStr | Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center |
title_full_unstemmed | Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center |
title_short | Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center |
title_sort | clinical phenotypes and the clinical course of bullous pemphigoid receiving dipeptidyl pepitidase-4 inhibitor treatment: an analysis of cases in a single japanese center |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332970/ https://www.ncbi.nlm.nih.gov/pubmed/36328578 http://dx.doi.org/10.2169/internalmedicine.0815-22 |
work_keys_str_mv | AT nakagawayosuke clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter AT toyodamasao clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter AT saitonobumichi clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter AT kaneyamanoriko clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter AT shimizutomomichi clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter AT mabuchitomotaka clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter AT fukagawamasafumi clinicalphenotypesandtheclinicalcourseofbullouspemphigoidreceivingdipeptidylpepitidase4inhibitortreatmentananalysisofcasesinasinglejapanesecenter |